Zobrazeno 1 - 10
of 83
pro vyhledávání: '"S. Bessmeltsev"'
Autor:
Institute Of Hematology And Transfusiology, St.Pet, V. Burylev, I. Kostroma, E. Kiseleva, N. Stizhak, E. Kaytandzhan, S. Gritsaev, S. Bessmeltsev, V. Chebotkevich
Publikováno v:
HemaSphere, Vol 6, Pp 1466-1467 (2022)
Externí odkaz:
https://doaj.org/article/d41b380ec80f4a13878ba9fda4b21166
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 22-28 (2022)
In this article mechanisms of anaemia development in patients with lymphatic tissue malignant diseases are presented. Therapy efficacy of erythropoiesis-stimulating agents (EPO) in patients with lymphoproliferative disorders and anaemia (n = 21) is s
Externí odkaz:
https://doaj.org/article/0e4ef83caabe4f74bd9265350f9824e9
Autor:
S. S. Bessmeltsev, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 73-78 (2022)
The aim of the investigation was to estimate Vero-Fludarabine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients. We report the activity of three combinations of Vero-Fludarabine, one with cyclophosphamide (Vero-FluCy), the second
Externí odkaz:
https://doaj.org/article/39b34bd8208c4ebdadaab5e49b0816d9
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, E. I. Podoltseva, E. V. Kariagina, G. N. Salogub, А. S. Nisamutdinova, L. M. Matuhina, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 61-66 (2022)
Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a me
Externí odkaz:
https://doaj.org/article/8553a7bdc296417c8a2e1b3fa806ced5
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, N. V. Stepanova, K. M. Abdulkadyrov, G. N. Salogub, E. R. Machulaitene, E. V. Kariagina
Publikováno v:
Онкогематология, Vol 0, Iss 2, Pp 40-45 (2022)
We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 6
Externí odkaz:
https://doaj.org/article/b683f210247445cdb987afa77e18fa09
Autor:
S. S. Bessmeltsev, E. V. Karyagina, L. V Stelmashenko, N. V. Stepanova, E. R. Machulaiten, G. N. Salogub, I. A. Skorokhod, N. V. Medvedeva, E. I. Podoltseva, L. M. Matyukhina, A. S. Nizamutdinova, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 52-62 (2022)
The characteristics of peripheral neuropathy (PN), its incidence and a possibility of relieving in multiple myeloma (MM) patients receiving bortezomib are presented. A hundred and twenty-four patients with recurrent/refractory MM and 14 primary patie
Externí odkaz:
https://doaj.org/article/d13b8f52d7bd41c4a2309ca155e24f5c
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 15-22 (2022)
Efficiency of alemtuzumab (Campath) in 8 patients with chronic lymphocytic leukemia (CLL) was reported. Patients treated with alemtuzumab or alemtuzumab in combination with fludarabine (FluCam). Therapy response, overall survival and incidence of sid
Externí odkaz:
https://doaj.org/article/2794f39681354c5583e3cb76794443c7
Autor:
N. A. Romanenko, S. S. Bessmeltsev, V. I. Rugal, N. A. Potichonova, M. N. Zenina, K. M. Abdulkadirov
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 61-68 (2022)
Case report of a patient with simultaneously developed lymphoid and myeloid hemoblastosis is presented. Diagnosis of multiple myeloma and chronic idiopathic myelofibrosis are confirmed by complete blood count, myelogramm, trephinebiopsy, immunohistoc
Externí odkaz:
https://doaj.org/article/716204851850427bb65131afee47f38e
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 39-47 (2022)
A lymphocyte lineage which is referred to as NKT cells expresses both markers of NK cells and T lymphocytes. NKT cells play a key role in the regulation of different types of immune responses, contribute to the protection from tumor growth and metast
Externí odkaz:
https://doaj.org/article/9b1d3d4b85b64275b26dadac8cf7d693
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, E. V. Kariagina, N. V. Stepanova, G. N. Salogub, T. L. Shelkovskaya, T. A. Malakhova, I. A. Skorokhod, E. I. Podoltseva, N. O. Saraeva, O. I. Kovalev, A. V. Klimovich, N. V. Medvedeva, K. M. Abdulkadyrov, L. I. Krylova, T. H. Potrachkova, M. A. Novikova, E. R. Machulaitene, E. I. Darskaya, L. M. Matukhina, N. A. Kotova, O. Ya. Kostina, I. A. Novokreshchenova
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 6-13 (2022)
We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate
Externí odkaz:
https://doaj.org/article/c2efdc3ba2154cfb809d445aa9adf43d